Improving early detection and treatment of atrial fibrillation (AF) is critical because untreated AF is a major contributor to stroke and heart failure. We sought to generate knowledge about the feasibility of conducting a randomized controlled trial to test the effect of the Alert for AFib intervention on knowledge, attitudes, and beliefs about treatment-seeking for signs and symptoms of AF. Adults ≥65 years old (96% White) at risk for developing AF were randomized to receive the Alert for AFib intervention ( n = 40) or an attention control session ( n = 40). Feasibility goals for recruitment, participant retention, adherence, perceived satisfaction and burden, and intervention fidelity were met. From baseline to study completion, knowledge ( p = .005) and attitudes ( p < .001) about treatment-seeking improved more in the intervention group compared with the control group. Results support testing the effectiveness of the Alert for AFib intervention in a large trial.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5347363 | PMC |
http://dx.doi.org/10.1177/0193945916656609 | DOI Listing |
Introduction Parenteral heparin is widely used as bridging therapy while optimising oral anticoagulation(OAC). Newer Direct-Acting OACs(DOACs) attain therapeutic effect very quickly. We report the use of dabigatran as bridging therapy during warfarin optimization for cardioembolic stroke in two patients who opted to receive warfarin for long-term anticoagulation for secondary stroke prevention.
View Article and Find Full Text PDFHeartRhythm Case Rep
November 2024
Helmsley Center for Electrophysiology, Icahn School of Medicine at Mount Sinai, New York.
Heliyon
December 2024
Centro Cardiologico Monzino IRCCS, 20138, Milan, Italy.
Background: Traditional screening methods, such as 12-lead electrocardiograms (ECGs) and Holter monitors, often fall short in detecting transient arrhythmias. However, advancements in wearable technology, like the Apple Watch®, enable real-time rhythm monitoring and specific arrhythmia detection through dedicated algorithms.
Case Description: A 60-year-old man with a history of arrhythmogenic cardiomyopathy and an implanted cardioverter-defibrillator (ICD), during a walk, experienced palpitations and dizziness; the Apple Watch® alerted him of an elevated heart rate.
J Med Internet Res
November 2024
Division of Cardiology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea.
Background: Adherence to oral anticoagulant therapy is essential to prevent ischemic stroke in patients with atrial fibrillation (AF).
Objective: This study aimed to evaluate whether smartphone app-based interventions improve medication adherence in patients with AF.
Methods: This open-label, multicenter randomized controlled trial (ADHERE-App [Self-Awareness of Drug Adherence to Edoxaban Using an Automatic App Feedback System] study) enrolled patients with AF treated with edoxaban for stroke prevention.
Heart Rhythm
October 2024
Cardiology and Arrhythmology Clinic, University Hospital "Azienda Ospedaliero-Universitaria delle Marche," Ancona, Italy; Department of Biomedical Sciences and Public Health, Marche Polytechnic University, Ancona, Italy.
Background: The HeartLogic algorithm (Boston Scientific, St Paul, MN) integrates data from implantable cardioverter-defibrillator (ICD) sensors to predict heart failure (HF) decompensation: first (S1) and third (S3) heart sounds, intrathoracic impedance, respiration rate, ratio of respiration rate to tidal volume (RSBI), and night heart rate.
Objective: This study assessed the relative changes in ICD sensors at the onset of HeartLogic alerts, their association with patient characteristics, and outcomes.
Methods: The study included 568 patients with HF carrying ICDs (CRT-D, n = 410) across 26 centers, with a median follow-up of 26 months.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!